{"id":"W2400894217","doi":"10.1182/blood.v126.23.727.727","title":"Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Ixazomib; Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Progression-free survival; Oncology; Internal medicine; Proteasome inhibitor; Pegfilgrastim; Miltefosine; Pharmacology; Febrile neutropenia; Neutropenia; Overall survival; Carfilzomib; Chemotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001199625,0.0003843199,0.0005312453,0.0002360411,0.0002301954,0.00009777791,0.0001852635,0.0001165538,0.000008435347],"category_scores_gemma":[0.001923512,0.0002078287,0.00003454944,0.0003532729,0.0003383557,0.0004590191,0.0001074213,0.0003370255,0.000001427619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001086391,"about_ca_system_score_gemma":0.0005534253,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002091289,"about_ca_topic_score_gemma":0.001290431,"domain_scores_codex":[0.9966999,0.0004838734,0.0004749221,0.0006751533,0.001173103,0.0004930294],"domain_scores_gemma":[0.9974265,0.0005328992,0.0002549548,0.0005360168,0.0005988522,0.0006508554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03847482,0.02547463,0.9138755,0.0001316693,0.0003648711,0.0002443804,0.001922245,0.000003132409,0.001057909,0.00002068273,0.00008632951,0.01834384],"study_design_scores_gemma":[0.3349409,0.05360078,0.6023321,0.0003961608,0.0004056385,0.00006653415,0.00238129,0.002043125,0.003130941,0.0001354821,0.0001320747,0.0004350264],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991762,0.0001191022,0.00005522908,0.0004454401,0.0000469737,0.007356996,0.0001278003,0.00006606012,0.00002039319],"genre_scores_gemma":[0.9898006,0.000008296461,0.007776378,0.00005205446,0.0001365947,0.001680873,0.0003705455,0.00006783177,0.0001068048],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3115434,"threshold_uncertainty_score":0.847501,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05309745008142338,"score_gpt":0.3334005016023233,"score_spread":0.2803030515209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}